Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Laser in-situ keratomileusis for residual refractive error after multifocal intraocular lens implantation in very high hyperopic patients

Poster Details

First Author: E. Levinger ISRAEL

Co Author(s):    O. Trivizki   S. Levinger                 

Abstract Details

Purpose:

To analyze the refractive outcome and report the results of combining multifocal intraocular lens (MIOL) implantation and excimer corneal surgery to treat very high hyperopia.

Setting:

Prospective noncomparative interventional case series

Methods:

10 eyes of 5 patients (mean age 31.08 ± 11.08, all females) with very high hyperopia (spherical equivalent +8.51 ± 0.86 D) had been treated with serial MIOL implantation and were retreated by laser in situ keratomileusis (LASIK) for residual hyperopia 6 weeks later. Uncorrected distance visual acuity (UDVA), near visual acuity (UNVA), corrected visual acuities (CDVA, and CNVA, distance and near respectively) and manifest refraction were evaluated before surgeries, after MIOL implantation and 1 month post-LASIK procedure.

Results:

There were no loss to follow-up. Mean spherical equivalent decreased to +2.05 ± 1.33 D after MIOL implantation and to -0.10 ± 0.58 D after the LASIK procedure. LogMAR UDVA has improved by total of more than 6 lines from mean of 1.06 ± 0.17 to 0.46 ± 0.12 post MIOL implantation and to 0.33 ± 0.22 after both surgeries. Although LogMAR UNVA has increased by more than 30% averagely to 0.8 ± 0.81 after lens implantation due to loss of accommodation and lack of proper refraction state. At 1 month postoperatively, all eyes have reached LogMAR of 0.

Conclusions:

Bioptics of MIOL followed 6 weeks later by LASIK procedure for correction of very high hyperopia allowed us to treat the total refractive error and reduced patient dependence on spectacles.

Financial Disclosure:

NONE

Back to Poster listing